Richard D. Carvajal, MD, has been named director of the Experimental Therapeutics/Phase I program and melanoma service in medical oncology at NewYork-Presbyterian/Columbia University Medical Center, effective Nov. 1, 2014.
A CUMC study found that the use of generic aromatase inhibitors, which cost considerably less than their brand-name counterparts, increased treatment adherence by 50 percent.
Using an innovative algorithm, CUMC researchers have found that loss of a gene called KLHL9 is the driving force behind the most aggressive form of glioblastoma, the most common form of brain cancer.
Research from Columbia shows that nerves play a critical role in stomach cancer growth and blocking nerve signals using surgery or Botox® could provide an effective therapy for the disease.
Patients considering morcellation should be counseled about the prevalence of cancerous and precancerous conditions prior to undergoing the procedure.